Urethral cancer differential diagnosis: Difference between revisions
Ahmed Younes (talk | contribs) No edit summary |
|||
(12 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Urethral_cancer]] | |||
{{CMG}}; {{AE}}{{MJ}}, {{Vbe}} | {{CMG}}; {{AE}}{{MJ}}, {{Vbe}} | ||
Line 7: | Line 7: | ||
==Differentiation== | ==Differentiation== | ||
[[Urethral cancer|Urethral]] [[cancer]] must be differentiated from other diseases that cause lower [[urinary tract]] irritation symptoms (e.g., [[dysuria]], urgency and frequency in addition to urethral [[discharge]]); these include [[Bladder cancer]], [[Cervical cancer]], urethritis, [[Bladder stones]], | [[Urethral cancer|Urethral]] [[cancer]] must be differentiated from other diseases that cause lower [[urinary tract]] irritation symptoms (e.g., [[dysuria]], urgency and frequency in addition to urethral [[discharge]]); these include [[Bladder cancer]], [[Cervical cancer]], [[urethritis]], [[Bladder stones]], [[cystitis]], urethrolithiasis, [[Neurogenic bladder]], [[cervicitis]], [[vaginitis|vulvovaginitis]], and [[Epididymo-orchitis|epididymitis]]'''.'''<ref name=":0">{{Cite journal | ||
| author = [[Stephen Bent]], [[Brahmajee K. Nallamothu]], [[David L. Simel]], [[Stephan D. Fihn]] & [[Sanjay Saint]] | | author = [[Stephen Bent]], [[Brahmajee K. Nallamothu]], [[David L. Simel]], [[Stephan D. Fihn]] & [[Sanjay Saint]] | ||
| title = Does this woman have an acute uncomplicated urinary tract infection? | | title = Does this woman have an acute uncomplicated urinary tract infection? | ||
Line 76: | Line 76: | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! rowspan="2" |<small>Diseases</small> | ! rowspan="2" |<small>Diseases</small> | ||
| colspan=" | | colspan="7" |<small>'''Symptoms''' | ||
! colspan="4" |<small>Physical Examination</small> | ! colspan="4" |<small>Physical Examination</small> | ||
! colspan="3" |<small>Diagnostic tests</small> | ! colspan="3" |<small>Diagnostic tests</small> | ||
! colspan="1" rowspan="2" |<small>Past medical history</small> | ! colspan="1" rowspan="2" |<small>Past medical history</small> | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
!<small>Hematuria</small> | !<small>Hematuria</small> | ||
Line 87: | Line 86: | ||
!<small>Urgency</small> | !<small>Urgency</small> | ||
!<small>Dysuria</small> | !<small>Dysuria</small> | ||
!<small>Weak urine stream<small> | |||
!<small>Mass<small> | |||
!<small>Fever</small> | !<small>Fever</small> | ||
!<small>Tenderness</small> | !<small>Tenderness</small> | ||
Line 94: | Line 95: | ||
!<small>Urine Culture</small> | !<small>Urine Culture</small> | ||
!<small>Gold Standard | !<small>Gold Standard | ||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Urethral Cancer | |||
| align="center" style="background:#F5F5F5;" + | + | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + | +/– | |||
| align="center" style="background:#F5F5F5;" + | +/– | |||
| align="center" style="background:#F5F5F5;" + | +/– | |||
| align="center" style="background:#F5F5F5;" + | + | |||
| align="center" style="background:#F5F5F5;" + | + | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |Malignant cells | |||
RBC | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |Biopsy | |||
| align="center" style="background:#F5F5F5;" + | | |||
* Personal [[History and Physical examination|history]] of [[bladder cancer]]. | |||
* [[Conditions]] that cause [[chronic]] [[inflammation]] in the [[urethra]], including: | |||
:* [[Sexually transmitted diseases]] (STDs), including [[human papillomavirus]] (especially HPV type 16) | |||
:* Frequent [[urinary tract infections]] (UTIs) | |||
:* White female | |||
:* Age 60 | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Bladder cancer]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Bladder cancer]] | ||
Line 99: | Line 125: | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | +/– | | align="center" style="background:#F5F5F5;" + | +/– | ||
| align="center" style="background:#F5F5F5;" + | +/– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + | +/– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |Malignant cells | |||
RBC | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |Biopsy | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Smoking | |||
* Occupational exposure to chemicals: Textiles, Rubber, Paint, Leather, Dye, Metal, Machining, Plastics, [[Arsenic]], Aristolochic acids | |||
* Chronic bladder irritation | |||
* Chronic [[urinary tract infection]] | |||
* [[Bladder stones]] | |||
* ''[[Schistosoma haematobium]]'' | |||
* Trauma | |||
* [[Chemotherapy]]: [[Cyclophosphamide|yclophosphamide]], [[Ifosfamide]] | |||
* [[Radiation therapy]] | |||
| | * Personal history of cancer in the [[urinary tract]] | ||
* [[Congenital]] bladder anomalies such as [[Urachus|rachus]], Exstrophy | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cervical cancer]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cervical cancer]] | ||
Line 115: | Line 156: | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | +/– | | align="center" style="background:#F5F5F5;" + | +/– | ||
| align="center" style="background:#F5F5F5;" + | +/– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + | +/– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |Biopsy | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
*'''Specific risk factor: Human papillomavirus (HPV) infection''':<ref>[http://www.cancer.org/docroot/CRI/content/CRI_2_2_2X_What_causes_cancer_of_the_cervix_Can_it_be_prevented_8.asp?sitearea=] American Cancer Society</ref><ref>[http://www.mdlab.com/html/testing/hpv_typedetect.html]</ref><ref>[http://www.cancer.gov/newscenter/benchmarks-vol2-issue4/page2]</ref><ref>[http://www.cancer.gov/cancertopics/factsheet/Risk/HPV]</ref> | |||
| | |||
| | *Other risk factors for cervical cancer include the following: <ref name="pmid30212064">{{cite journal |vauthors=Kim JJ, Burger EA, Regan C, Sy S |title= |journal= |volume= |issue= |pages= |date= |pmid=30212064 |doi= |url=}}</ref><ref name="pmid30172799">{{cite journal |vauthors=Tatar O, Thompson E, Naz A, Perez S, Shapiro GK, Wade K, Zimet G, Gilca V, Janda M, Kahn J, Daley E, Rosberger Z |title=Factors associated with human papillomavirus (HPV) test acceptability in primary screening for cervical cancer: A mixed methods research synthesis |journal=Prev Med |volume=116 |issue= |pages=40–50 |date=November 2018 |pmid=30172799 |doi=10.1016/j.ypmed.2018.08.034 |url=}}</ref> | ||
| | ::*'''Smoking''' | ||
| | ::*'''HIV infection''' | ||
| | |||
| | ::*'''Increased number of sexual partners''' | ||
| | |||
::*'''Young age at time of first sexual intercourse''' | |||
::*'''Hormonal contraception''' | |||
::*'''High parity''' '''DES (diethylstilbestrol)''': | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Bladder stones]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Bladder stones]] | ||
Line 131: | Line 187: | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + |+/– | | align="center" style="background:#F5F5F5;" + | +/– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | +/– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |RBC | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + |CT scan without contrast | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Common risk factors in the development of nephrolithiasis include: | |||
* Dietary habits | |||
* Low urinary pH | |||
* [[Hypercalcemia]] | |||
* [[Hypercalciuria]] | |||
* [[Hyperoxaluria]] | |||
* [[Hyperuricemia]] | |||
* [[Hyperuricosuria]] | |||
* [[Metabolic syndrome]] | |||
* [[Obesity]] | |||
* [[Diabetes mellitus]] | |||
* Environmental - such as hot climate | |||
* Drugs | |||
** [[Thiazide]] | |||
** [[Furosemide]] | |||
** [[Sulfadiazine]] | |||
** [[Indinavir]] | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Ureterolithiasis | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | +/– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |RBC | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |CT scan without contrast | ||
| align="center" style="background:#F5F5F5;" + |Same as bladder cancer | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Neurogenic bladder]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Neurogenic bladder]] | ||
Line 163: | Line 238: | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | +/– | | align="center" style="background:#F5F5F5;" + | +/– | ||
| align="center" style="background:#F5F5F5;" + |+/– | | align="center" style="background:#F5F5F5;" + | +/– | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
Line 169: | Line 244: | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |Urodynamic study (UDS) | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Spinal cord diseases, injuries | |||
* Neural tube defects including [[spina bifida]]. | |||
* [[Brain tumor]]s | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urethritis|'''Urethritis''']] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urethritis|'''Urethritis''']] | ||
Line 181: | Line 260: | ||
| align="center" style="background:#F5F5F5;" + | – | | align="center" style="background:#F5F5F5;" + | – | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | +/– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | – | | align="center" style="background:#F5F5F5;" + | – | ||
Line 196: | Line 277: | ||
* Recent intercourse | * Recent intercourse | ||
* Recent [[catheterization]] | * Recent [[catheterization]] | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Cystitis|'''Cystitis''']] | | style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Cystitis|'''Cystitis''']] | ||
Line 207: | Line 284: | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + |– | |||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | Suprapubic | | align="center" style="background:#F5F5F5;" + | Suprapubic | ||
Line 227: | Line 306: | ||
*[[BPH]] | *[[BPH]] | ||
*[[HIV]] | *[[HIV]] | ||
|- | |- | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! rowspan="2" |<small>Diseases</small> | ! rowspan="2" |<small>Diseases</small> | ||
| colspan=" | | colspan="7" |<small>'''Symptoms''' | ||
! colspan="4" |<small>Physical Examination</small> | ! colspan="4" |<small>Physical Examination</small> | ||
! colspan="3" |<small>Diagnostic tests</small> | ! colspan="3" |<small>Diagnostic tests</small> | ||
! colspan="1" rowspan="2" |<small>Past medical history</small> | ! colspan="1" rowspan="2" |<small>Past medical history</small> | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
!<small>Hematuria</small> | !<small>Hematuria</small> | ||
Line 244: | Line 319: | ||
!<small>Urgency</small> | !<small>Urgency</small> | ||
!<small>Dysuria</small> | !<small>Dysuria</small> | ||
!<small>Weak urine stream | |||
!<small>Mass<small> | |||
!<small>Fever</small> | !<small>Fever</small> | ||
!<small>Tenderness</small> | !<small>Tenderness</small> | ||
Line 258: | Line 335: | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | – | | align="center" style="background:#F5F5F5;" + | – | ||
Line 269: | Line 348: | ||
* Prior [[STDs]] | * Prior [[STDs]] | ||
* Previous history of symptomatic BV in female partner (in [[homosexual]] women) | * Previous history of symptomatic BV in female partner (in [[homosexual]] women) | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Cervicitis|'''Cervicitis''']] | | style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Cervicitis|'''Cervicitis''']] | ||
Line 281: | Line 355: | ||
| align="center" style="background:#F5F5F5;" + | – | | align="center" style="background:#F5F5F5;" + | – | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | Cervical | | align="center" style="background:#F5F5F5;" + | Cervical | ||
Line 293: | Line 369: | ||
* Painful sexual intercourse | * Painful sexual intercourse | ||
* Pressure or heaviness in the [[pelvis]] | * Pressure or heaviness in the [[pelvis]] | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Epididymitis|'''Epididymitis''']] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Epididymitis|'''Epididymitis''']] | ||
Line 304: | Line 376: | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | [[Testicular]] & suprapubic | | align="center" style="background:#F5F5F5;" + | [[Testicular]] & suprapubic | ||
Line 317: | Line 391: | ||
*[[Scrotum|Scrotal]] wall [[erythema]] | *[[Scrotum|Scrotal]] wall [[erythema]] | ||
*Constitutional symptoms: feeling warm, [[chills]], [[nausea and vomiting]] | *Constitutional symptoms: feeling warm, [[chills]], [[nausea and vomiting]] | ||
|- | |- | ||
|} | |} |
Latest revision as of 21:28, 14 February 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [5]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [6], Vindhya BellamKonda, M.B.B.S [7]
Overview
Urethral cancer must be differentiated from bladder cancer, cervical cancer, bladder stones, ureteral stones, cystitis, neurogenic bladder, and urethritis.
Differentiation
Urethral cancer must be differentiated from other diseases that cause lower urinary tract irritation symptoms (e.g., dysuria, urgency and frequency in addition to urethral discharge); these include Bladder cancer, Cervical cancer, urethritis, Bladder stones, cystitis, urethrolithiasis, Neurogenic bladder, cervicitis, vulvovaginitis, and epididymitis.[1][2][3][4][5][6][7][8][9][10][11]
Diseases | Symptoms | Physical Examination | Diagnostic tests | Past medical history | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hematuria | Pyuria | Frequency | Urgency | Dysuria | Weak urine stream | Mass | Fever | Tenderness | Discharge | Inguinal Lymphadenopathy | Urinalysis | Urine Culture | Gold Standard | ||
Urethral Cancer | + | – | +/– | +/– | +/– | + | + | – | – | – | – | Malignant cells
RBC |
– | Biopsy |
|
Bladder cancer | + | – | +/– | +/– | – | – | +/– | – | – | – | – | Malignant cells
RBC |
– | Biopsy |
|
Cervical cancer | – | – | +/– | +/– | – | – | +/– | – | – | – | – | – | – | Biopsy |
|
Bladder stones | + | – | + | +/– | +/– | – | – | – | – | – | – | RBC | – | CT scan without contrast |
Common risk factors in the development of nephrolithiasis include:
|
Ureterolithiasis | + | – | + | + | +/– | – | – | – | – | – | – | RBC | – | CT scan without contrast | Same as bladder cancer |
Neurogenic bladder | – | – | +/– | +/– | – | – | – | – | – | – | – | – | – | Urodynamic study (UDS) |
|
Urethritis | – | + | – | – | + | +/– | – | + | – | Urethral discharge | + |
|
– | Gram stain & mucoid or purulent discharge |
|
Cystitis | + | + | + | + | + | – | – | + | Suprapubic | – | + |
|
>100,000CFU/mL | Urine culture |
|
Diseases | Symptoms | Physical Examination | Diagnostic tests | Past medical history | |||||||||||
Hematuria | Pyuria | Frequency | Urgency | Dysuria | Weak urine stream | Mass | Fever | Tenderness | Discharge | Inguinal Lymphadenopathy | Urinalysis | Urine Culture | Gold Standard | ||
Vulvovagintis | – | – | – | – | + | + | – | Vaginal discharge | + | – | – | Gram stain & culture of discharge |
| ||
Cervicitis | – | + | – | – | + | + | Cervical | Endocervical exudate | – | – | – | Culture for gonococcal cervicitis |
| ||
Epididymitis | + | – | + | + | + | + | Testicular & suprapubic | +/– urethral discharge | + |
|
+ | Culture |
|
References
- ↑ Stephen Bent, Brahmajee K. Nallamothu, David L. Simel, Stephan D. Fihn & Sanjay Saint (2002). "Does this woman have an acute uncomplicated urinary tract infection?". JAMA. 287 (20): 2701–2710. PMID 12020306. Unknown parameter
|month=
ignored (help) - ↑ W. E. Stamm (1981). "Etiology and management of the acute urethral syndrome". Sexually transmitted diseases. 8 (3): 235–238. PMID 7292216. Unknown parameter
|month=
ignored (help) - ↑ W. E. Stamm, K. F. Wagner, R. Amsel, E. R. Alexander, M. Turck, G. W. Counts & K. K. Holmes (1980). "Causes of the acute urethral syndrome in women". The New England journal of medicine. 303 (8): 409–415. doi:10.1056/NEJM198008213030801. PMID 6993946. Unknown parameter
|month=
ignored (help) - ↑ Leonie G. M. Giesen, Grainne Cousins, Borislav D. Dimitrov, Floris A. van de Laar & Tom Fahey (2010). "Predicting acute uncomplicated urinary tract infection in women: a systematic review of the diagnostic accuracy of symptoms and signs". BMC family practice. 11: 78. doi:10.1186/1471-2296-11-78. PMID 20969801.
- ↑ Taylor-Robinson D (1996). "The history of nongonococcal urethritis. Thomas Parran Award Lecture". Sex Transm Dis. 23 (1): 86–91. PMID 8801649.
- ↑ Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 9781455748013.
- ↑ Brill JR (2010). "Diagnosis and treatment of urethritis in men". Am Fam Physician. 81 (7): 873–8. PMID 20353145.
- ↑ Daniel V. Landers, Harold C. Wiesenfeld, R. Phillip Heine, Marijane A. Krohn & Sharon L. Hillier (2004). "Predictive value of the clinical diagnosis of lower genital tract infection in women". American journal of obstetrics and gynecology. 190 (4): 1004–1010. doi:10.1016/j.ajog.2004.02.015. PMID 15118630. Unknown parameter
|month=
ignored (help) - ↑ Felix Millan-Rodriguez, J. Palou, Anna Bujons-Tur, Mireia Musquera-Felip, Carlota Sevilla-Cecilia, Marc Serrallach-Orejas, Carlos Baez-Angles & Humberto Villavicencio-Mavrich (2006). "Acute bacterial prostatitis: two different sub-categories according to a previous manipulation of the lower urinary tract". World journal of urology. 24 (1): 45–50. doi:10.1007/s00345-005-0040-4. PMID 16437219. Unknown parameter
|month=
ignored (help) - ↑ Kim TH, Kim SY, Moon KC, Lee J, Cho JY, Kim SH (April 2017). "Clear Cell Adenocarcinoma of the Urethra in Women: Distinctive MRI Findings for Differentiation From Nonadenocarcinoma and Non-Clear Cell Adenocarcinoma of the Urethra". AJR Am J Roentgenol. 208 (4): 805–811. doi:10.2214/AJR.16.16929. PMID 28140610.
- ↑ Cantiello F, Cicione A, Salonia A, Autorino R, Tucci L, Madeo I, Damiano R (May 2013). "Periurethral fibrosis secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort study". Urology. 81 (5): 1018–23. doi:10.1016/j.urology.2013.01.053. PMID 23608423.
- ↑ [1] American Cancer Society
- ↑ [2]
- ↑ [3]
- ↑ [4]
- ↑ Kim JJ, Burger EA, Regan C, Sy S. PMID 30212064. Missing or empty
|title=
(help) - ↑ Tatar O, Thompson E, Naz A, Perez S, Shapiro GK, Wade K, Zimet G, Gilca V, Janda M, Kahn J, Daley E, Rosberger Z (November 2018). "Factors associated with human papillomavirus (HPV) test acceptability in primary screening for cervical cancer: A mixed methods research synthesis". Prev Med. 116: 40–50. doi:10.1016/j.ypmed.2018.08.034. PMID 30172799.